Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: TokyoMex who wrote (21365)	12/3/1998 11:49:00 AM
From: Ron	Respond to of 119973

TM..look at BIOMF..another breakout...

To: TokyoMex who wrote (21365)	12/3/1998 11:49:00 AM
From: Susan Saline	Respond to of 119973

BIOMF in play again today ... Thursday December 3, 11:18 am Eastern Time Company Press Release SOURCE: Biomira Inc. Biomira Fully Enrolled in Phase I Lung Cancer Trial - Company concludes safety study on schedule EDMONTON, ALBERTA, CANADA, Dec. 3 /CNW-PRN/ - Biomira Inc. (NASDAQ: BIOMF - news; TSE, ME: BRA - news) announced today that it has completed enrollment for a safety and dose comparison study of its new synthetic MUC-1 cancer vaccine in 14 patients with non-small cell lung cancer. ''The program is moving forward on schedule,'' said Dr. Alex McPherson, Biomira's President and CEO. ''We will be analyzing the data as we continue to monitor patients and plan to announce our findings in the first quarter of 1999.'' The proprietary vaccine, BLP25, is a 25-amino acid sequence of the MUC-1 mucin, encapsulated in a liposomal delivery system (fat droplets smaller than red blood cells) to enhance recognition by the immune system. Lung cancer is the leading cause of death in both men and women in North America. With an estimated 149,000 new cases reported each year, there were 133,000 deaths due to lung cancer in 1997 alone. To date, chemotherapy has only improved survival modestly. Biomira's technology provides a novel approach to treating the disease with the goal of prolonging life. ''We believe BLP25 could play an important role in treating lung cancer,'' said Dr. Grant MacLean, the Company's Vice President of Clinical and Regulatory Affairs. ''We also believe the vaccine has great potential in the treatment of other cancers.'' The therapeutic vaccine strategy involves using a synthetic mimic of a well-defined cancer antigen. The vaccine is injected under the skin to stimulate an immune response to the antigen, and thus, also to patients' cancer cells, to prevent growth and spread of their cancers.'' In pre-clinical studies, BLP25 prevented the appearance of lung metastases when given in advance of a cancer cell line expressing human MUC-1. In other BLP25 experiments, where the vaccine was given after cancer nodules had already developed in the lung, the cancer cells were almost entirely eradicated. Biomira has secured world-wide rights to the MUC-1 vaccine, through its licensing of patents from the Dana-Farber Cancer Institute and the Imperial Cancer Research Fund's technology transfer company, Imperial Cancer Research Technology Limited in London, England. The current trial is being held at the Cross Cancer Institute in Edmonton. Biomira is developing a portfolio of complementary cancer vaccine candidates. The Company launched a major Phase III trial with its lead product candidate, THERATOPE® vaccine, in 900 metastatic breast cancer patients in North America and Europe at the end of last month. Plans also call for a Phase I trial for an idiotypic vaccine, tailor made from patients' own specific cancer cells, involving lymphoma patients in 1999. Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. The commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy. We are The Cancer Vaccine People™. This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing of clinical trials or the efficacy of products. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement. SOURCE: Biomira Inc.

To: TokyoMex who wrote (21365)	12/3/1998 11:50:00 AM
From: R Hamilton	Respond to of 119973

you can say that again........here, i'll do it for you <G> market sucks today,,,,,,,,market sucks today

To: TokyoMex who wrote (21365)	12/3/1998 11:50:00 AM
From: DO$Kapital	Read Replies (3) \| Respond to of 119973

In SHRP,,,broker down again, DAMN!